Immune thrombocytopenia secondary to COVID-19: a systematic review

S Bhattacharjee, M Banerjee - SN comprehensive clinical medicine, 2020‏ - Springer
Immune thrombocytopenia, often known as immune thrombocytopenic purpura (ITP), has
emerged as an important complication of COVID-19. A systematic review was done to …

How we treat primary immune thrombocytopenia in adults

X Liu, Y Hou, M Hou - Journal of Hematology & Oncology, 2023‏ - Springer
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023‏ - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update

BJ Schneider, J Naidoo, BD Santomasso… - Journal of Clinical …, 2021‏ - ascopubs.org
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia

Y Chen, Y Xu, H Li, T Sun, X Cao, Y Wang… - … England Journal of …, 2024‏ - Mass Medical Soc
Background Immune thrombocytopenia (ITP) is an autoimmune disease characterized by
autoantibody-mediated platelet destruction. Treatment with CM313, a novel anti-CD38 …

Immune thrombocytopenic purpura in a patient with Covid-19

AA Zulfiqar, N Lorenzo-Villalba… - New England Journal …, 2020‏ - Mass Medical Soc
Immune Thrombocytopenic Purpura in a Patient with Covid-19 | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia

DJ Kuter, M Efraim, J Mayer, M Trněný… - … England Journal of …, 2022‏ - Mass Medical Soc
Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …

Asplenia and spleen hypofunction

MV Lenti, S Luu, R Carsetti, F Osier… - Nature Reviews …, 2022‏ - nature.com
Asplenia (the congenital or acquired absence of the spleen) and hyposplenism (defective
spleen function) are common causes of morbidity and mortality. The spleen is a secondary …

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised …

CM Broome, V McDonald, Y Miyakawa, M Carpenedo… - The Lancet, 2023‏ - thelancet.com
Background Primary immune thrombocytopenia is an autoimmune disorder mediated partly
by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional …

Mycophenolate mofetil for first-line treatment of immune thrombocytopenia

CA Bradbury, J Pell, Q Hill, C Bagot… - … England Journal of …, 2021‏ - Mass Medical Soc
Background Immune thrombocytopenia is a rare autoimmune disorder with associated
bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia …